ClinicaliQ Trial Snapshot
- A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs — Recruiting • Phase III • Diabetes / Metabolic • NCT06930625.
- A new drug (Debio 4126) tested against placebo to control growth hormone levels in acromegaly patients previously treated with somatostatin analogs.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison to placebo at week 36. Conditions: Acromegaly Interventions: Debio 4126, Placebo Lead Sponsor: Debiopharm International SA Planned Enrollment: 119 participants